한글목차

본 보고서는 REBYOTA 의약품의 주요 7개 시장(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본)을 조사 분석하여 작용기전, 용법 및 용량, 연구개발 활동에 대한 고찰과 시장 전망 등을 제공합니다.

목차

제1장 보고서 서론

제2장 크로스트리듐디피실 감염증용 REBYOTA 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제상 마일스톤
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 신규 치료법)

제5장 REBYOTA 시장 평가

• 크로스트리듐디피실 감염증용 REBYOTA 시장 전망
• 주요 7개국 분석
  • 주요 7개국의 크로스트리듐디피실 감염증용 REBYOTA 시장 규모
• 시장 분석 : 국가별
  • 미국의 크로스트리듐디피실 감염증용 REBYOTA 시장 규모
  • 독일의 크로스트리듐디피실 감염증용 REBYOTA 시장 규모
  • 영국의 크로스트리듐디피실 감염증용 REBYOTA 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight에 대해

제12장 보고서 구입 옵션

영문목차

“"REBYOTA Drug Insight and Market Forecast - 2032" report provides comprehensive insights about REBYOTA for clostridium difficile infection (CDI) in the seven major markets. A detailed picture of the REBYOTA for clostridium difficile infection in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the REBYOTA for clostridium difficile infection. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the REBYOTA market forecast analysis for clostridium difficile infection in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in clostridium difficile infection.

Drug Summary:

REBYOTA (RBX2660), being developed by Ferring Pharmaceuticals, is a first-in-class microbiota-based live biotherapeutic product to deliver a broad consortium of diverse microbes to the gut to reduce rCDI after antibiotic treatment.

Ferring Pharmaceuticals reported successful results from the Phase III PUNCH CD3 clinical trial demonstrating superior efficacy and consistent safety of single-dose RBX2660 in reducing the recurrence of CDI over placebo.

The company has leveraged its clinical, manufacturing, and regulatory experience with RBX2660 to develop a lyophilized non-frozen oral capsule formulation RBX7455. Ferring plans on conducting a Phase III study of RBX7455, which enhances the clinical pipeline of human microbiome-directed drug candidates.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the REBYOTA description, mechanism of action, dosage and administration, research and development activities in clostridium difficile infection.
• Elaborated details on REBYOTA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the REBYOTA research and development activities in clostridium difficile infection across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around REBYOTA.
• The report contains forecasted sales of REBYOTA for clostridium difficile infection till 2032.
• Comprehensive coverage of the late-stage emerging therapies for clostridium difficile infection.
• The report also features the SWOT analysis with analyst views for REBYOTA in clostridium difficile infection.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

REBYOTA Analytical Perspective by DelveInsight

In-depth REBYOTA Market Assessment

This report provides a detailed market assessment of REBYOTA for clostridium difficile infection in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

REBYOTA Clinical Assessment

The report provides the clinical trials information of REBYOTA for clostridium difficile infection covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for clostridium difficile infection is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence REBYOTA dominance.
• Other emerging products for clostridium difficile infection are expected to give tough market competition to REBYOTA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of REBYOTA in clostridium difficile infection.
• Our in-depth analysis of the forecasted sales data of REBYOTA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the REBYOTA in clostridium difficile infection.

Key Questions:

• What is the product type, route of administration and mechanism of action of REBYOTA?
• What is the clinical trial status of the study related to REBYOTA in clostridium difficile infection and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the REBYOTA development?
• What are the key designations that have been granted to REBYOTA for clostridium difficile infection?
• What is the forecasted market scenario of REBYOTA for clostridium difficile infection?
• What are the forecasted sales of REBYOTA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to REBYOTA for clostridium difficile infection?
• Which are the late-stage emerging therapies under development for the treatment of clostridium difficile infection?

Table of Contents

1. Report Introduction

2. REBYOTA Overview in Clostridium difficile infection

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. REBYOTA Market Assessment

• 5.1. Market Outlook of REBYOTA in Clostridium difficile infection
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of REBYOTA in the 7MM for Clostridium difficile infection
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of REBYOTA in the United States for Clostridium difficile infection
  • 5.3.2. Market Size of REBYOTA in Germany for Clostridium difficile infection
  • 5.3.3. Market Size of REBYOTA in France for Clostridium difficile infection
  • 5.3.4. Market Size of REBYOTA in Italy for Clostridium difficile infection
  • 5.3.5. Market Size of REBYOTA in Spain for Clostridium difficile infection
  • 5.3.6. Market Size of REBYOTA in the United Kingdom for Clostridium difficile infection
  • 5.3.7. Market Size of REBYOTA in Japan for Clostridium difficile infection

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options